5 Revealing Analyst Questions From Aflac’s Q2 Earnings Call

Aflac’s second quarter results were met with a negative market reaction, as sales declined year-over-year despite meeting Wall Street’s expectations. Management attributed the drop in revenue largely to tough comparisons in Japan following last year’s launch of the Miraito cancer insurance product, as well as shifting consumer preferences. CEO Daniel Amos emphasized that, while sales in Japan were down this quarter, new offerings like Tsumitasu and Anshin Palette produced solid growth. In the U.